Dr. Larisa Tereshchenko is recognized globally for her contributions to advancing cardiovascular care.
The Society for Clinical Trials (SCT) recognized Larisa Tereshchenko, MD, PhD, for leadership and outstanding service. The SCT is an international professional organization dedicated to the theory and practice of clinical trials. It boasts members from the academic, industry, government and non-profit sectors, all of whom are united in achieving the highest possible quality of clinical trials.
Dr. Tereshchenko serves as co-chair of the SCT 2022-2023 Education Committee and has been a member of the organization for over ten years. Over the past two decades, she has led multiple high-quality clinical trials that have improved how we understand and treat cardiac arrythmia.
In addition to her recognition by the SCT, this summer Dr. Tereshchenko won additional awards from American Heart Association and Cleveland Clinic Foundation. All four awards were granted in July of 2023.
One AHA award will fund a project called "Atrial Fibrillation Mapping Using Phase-Aligned Spectral Filtering for Decomposing Spatiotemporal Dynamics". Certain types of arrythmia can be cured by burning abnormal tissue. Dr. Tereshchenko’s project will develop better ways to locate the tissue to burn.
The second AHA award will fund a project called "Electrical desynchrony and heart failure." This project seeks to develop methods to detect early changes in the timing of how different regions of the heart contract in a heartbeat. Early treatment of these patients is crucial in preventing heart failure.
Dr. Tereshchenko also won a Cleveland Clinic Caregiver Catalyst Grant and a Case Western Reserve University School of Medicine Clinical and Translational Science Collaborative Award. These awards will fund two projects:
Caregiver Catalyst Grants are funded by external donations. To learn more about supporting our researchers, click here.
Researchers aim to use genomic findings to identify novel therapeutics.
How drugs and atrial fibrillation affect functions and genes in the body is the subject of a recent study into metformin and other candidate drugs.